human Aβ42

By Targets:	Amyloid-β (9) Isotope-Labeled Compounds (1) γ-secretase (1)
By Research Areas:	Neurological Disease (10)

Targets Recommended: Human leukocyte immunoglobulin (Ig)-like receptors (LILR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128581

γ-Secretase modulator 4	γ-secretase	Neurological Disease
γ-Secretase modulator 4 is a potent γ-secretase modulator, reduces the Aβ42 level with IC₅₀s of 0.014 μM and 0.017 μM in human and mouse, respectively .

HY-P990078

Remternetug LY3372993	Amyloid-β	Neurological Disease
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .

HY-P5905

*Citrullinated amyloid-β (1-42) peptide (human)* 1 Publications Verification Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P1363

*β-Amyloid (1-42), human* TFA** Maximum Cited Publications 16 Publications Verification Amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363A

β-Amyloid (1-42), human Maximum Cited Publications 16 Publications Verification Amyloid β-peptide (1-42) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363B

*β-Amyloid (1-42), human, HFIP-treated* Maximum Cited Publications 16 Publications Verification	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide *that has been treated with HFIP from β-Amyloid (1-42), human* (HY-P1363A)*, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity*; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363S1

*β-Amyloid (1-42), human, Ala(13C3,15N) TFA*	Isotope-Labeled Compounds Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P990301

*Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2)*	Amyloid-β	Neurological Disease
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .

HY-175755

Ac-BIM-acid bromide	Amyloid-β	Neurological Disease
Ac-BIM-acid bromide is a derivative of Acridine. Ac-BIM-acid bromide significantly inhibits amyloid fibrillation. Ac-BIM-acid bromide modulates the structure of N-terminal region of Saccharomyces cerevisiae Stm1 protein (Stm1_N ^1-113) and the amyloid morphology of human Aβ42 protein, inhibiting theirs growth. Ac-BIM-acid bromide can be used for Alzheimer’s disease research .

HY-P991073

MEDI-1814	Amyloid-β	Neurological Disease
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Target	Research Area

HY-P5905

*Citrullinated amyloid-β (1-42) peptide (human)* 1 Publications Verification Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P1363

*β-Amyloid (1-42), human* TFA** Maximum Cited Publications 16 Publications Verification Amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363A

β-Amyloid (1-42), human Maximum Cited Publications 16 Publications Verification Amyloid β-peptide (1-42) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363B

*β-Amyloid (1-42), human, HFIP-treated* Maximum Cited Publications 16 Publications Verification	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide *that has been treated with HFIP from β-Amyloid (1-42), human* (HY-P1363A)*, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity*; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363S1

*β-Amyloid (1-42), human, Ala(13C3,15N) TFA*	Isotope-Labeled Compounds Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

Cat. No.	Product Name	Target	Research Area

HY-P990078

Remternetug LY3372993	Amyloid-β	Neurological Disease
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .

HY-P990301

*Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2)*	Amyloid-β	Neurological Disease
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .

HY-P991073

MEDI-1814	Amyloid-β	Neurological Disease
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Chemical Structure

HY-P1363S1

*β-Amyloid (1-42), human, Ala(13C3,15N) TFA*
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

β-Amyloid (1-42), human, Ala(13C3,15N) TFA

β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.